225 related articles for article (PubMed ID: 27893325)
1. Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency.
Cunanan KM; Gonen M; Shen R; Hyman DM; Riely GJ; Begg CB; Iasonos A
J Clin Oncol; 2017 Jan; 35(3):271-273. PubMed ID: 27893325
[No Abstract] [Full Text] [Related]
2. American Society of Clinical Oncology--41st annual meeting. Drug highlights II.
Shah S; Yager N
IDrugs; 2005 Jul; 8(7):534-6. PubMed ID: 15973556
[No Abstract] [Full Text] [Related]
3. American society of clinical oncology--41st annual meeting. Immunology.
Shah S; Yager N
IDrugs; 2005 Jul; 8(7):528-30. PubMed ID: 15973554
[No Abstract] [Full Text] [Related]
4. American society of clinical oncology - 45th annual meeting. Part 2.
Lakeram M; Kibble A
IDrugs; 2009 Jul; 12(7):404-8. PubMed ID: 19579155
[No Abstract] [Full Text] [Related]
5. American society of clinical oncology - 45th annual meeting. Part 1.
Gale S
IDrugs; 2009 Jul; 12(7):401-3. PubMed ID: 19579154
[No Abstract] [Full Text] [Related]
6. American society of clinical oncology--41st annual meeting.
Shah S; Yager N
IDrugs; 2005 Jul; 8(7):525-7. PubMed ID: 15973553
[No Abstract] [Full Text] [Related]
7. New scale assesses benefits of cancer medicines.
Bagcchi S
Lancet Oncol; 2015 Jul; 16(7):e316. PubMed ID: 26051234
[No Abstract] [Full Text] [Related]
8. American Society of Clinical Oncology--44th Annual Meeting. Target identification and data from preclinical and clinical studies.
Kibble A
IDrugs; 2008 Aug; 11(8):541-4. PubMed ID: 18683082
[No Abstract] [Full Text] [Related]
9. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
10. [Clinical studies in oncology--a challenge for clinical and academic pathology].
Röcken C
Dtsch Med Wochenschr; 2013 May; 138(20):1073-6. PubMed ID: 23670265
[No Abstract] [Full Text] [Related]
11. Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer.
Morgensztern D; Pennell NA; Subramanian J; Govindan R
Clin Lung Cancer; 2011 Mar; 12(2):94-9. PubMed ID: 21550555
[TBL] [Abstract][Full Text] [Related]
12. Targeted drugs take centre stage at US cancer meeting.
McCarthy M
Lancet; 2001 May; 357(9268):1593. PubMed ID: 11377652
[No Abstract] [Full Text] [Related]
13. Epothilone D (Kosan/Roche).
Kolman A
Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
[TBL] [Abstract][Full Text] [Related]
14. MS-209 Schering.
Robert J
Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
[TBL] [Abstract][Full Text] [Related]
15. TG-4010 Transgene.
Cohen S; Kaufman HL
Curr Opin Investig Drugs; 2004 Dec; 5(12):1319-28. PubMed ID: 15648954
[TBL] [Abstract][Full Text] [Related]
16. Targeting mTOR for the treatment of AML. New agents and new directions.
Altman JK; Sassano A; Platanias LC
Oncotarget; 2011 Jun; 2(6):510-7. PubMed ID: 21680954
[TBL] [Abstract][Full Text] [Related]
17. Oncology trial design: More accurately and efficiently advancing the field.
Hohl RJ
Clin Pharmacol Ther; 2015 May; 97(5):430-2. PubMed ID: 25684240
[No Abstract] [Full Text] [Related]
18. Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.
Guazzelli A; Bakker E; Tian K; Demonacos C; Krstic-Demonacos M; Mutti L
Expert Opin Investig Drugs; 2017 Aug; 26(8):933-944. PubMed ID: 28679291
[TBL] [Abstract][Full Text] [Related]
19. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.
Amoroso L; Haupt R; Garaventa A; Ponzoni M
Expert Opin Investig Drugs; 2017 Nov; 26(11):1281-1293. PubMed ID: 28906153
[TBL] [Abstract][Full Text] [Related]
20. Ethical and Policy Issues for Seamless Phase I Oncology Trials.
Hutchinson N; Vinarov E; Iasonos A; Kimmelman J
J Clin Oncol; 2020 Mar; 38(7):669-673. PubMed ID: 31877086
[No Abstract] [Full Text] [Related]
[Next] [New Search]
